Medicamentos dinamizados injetáveis disponíveis no Brasil: indicações baseadas na homotoxicologia e possibilidades de uso pela visão antroposófica / Potentized injectable medicines available in Brazil: indications based on homotoxicology and possibilities of use according to anthroposophic medicine

A medicina biorreguladora utiliza medicamentos homeopáticos multicomponentes para tratar processos patológicos de forma harmônica à complexa rede fisiológica do organismo humano. No Brasil, dispomos atualmente de seis medicamentos injetáveis desta natureza: Traumeel® S, de ação anti-inflamatória; Zeel® comp. N para quadros de osteoartroses; Nux vomica-Homaccord®, para distúrbios gastrintestinais; Spascupreel®, para quadros espasmódicos de musculatura lisa e estriada; Gripp-Heel®, para quadros gripais e resfriados; e Vertigoheel®, para quadros vertiginosos, preparados segundo a farmacotécnica homeopática e indicados de acordo com as matérias médicas homeopáticas. Para cada medicação citada, existem estudos clínicos e in vitro para avaliação de eficácia, de seus mecanismos de ação farmacológicos e de seu perfil de tolerabilidade. De acordo com sua constituição homeopática, as medicações também serão analisadas sob a ótica da medicina antroposófica neste artigo. A biopuntura é uma técnica de administração parenteral destas medicações e segue os princípios de somatotopia e áreas de referência visceral. As administrações podem ser realizadas de forma subcutânea, intramuscular, intra-articular ou intravenosa. A utilização em milhares de pacientes destas medicações nos últimos sessenta anos mostrou-se extremamente segura e efetiva para as indicações aprovadas.(AU)

The bioregulatory medicine uses homeopathic multi-component drugs to treat pathological process in harmony to the complex physiologic net of the human organism. Currently, in Brazil there are six injectable medicines of this nature: Traumeel® S, with an anti-inflammatory action; Zeel® comp. N, for osteoarthritis conditions; Nux vomica-Hommacord®, for gastrointestinal disorders; Spascupreel®, for smooth and skeletal muscle spasmodic conditions; Gripp-Heel®, for common cold and influenza; and Vertigoheel® for vertigo; they have been prepared in accordance to the homeopathic pharmacopeia and indicated according to homeopathic materia medica. For each of these medications, there are clinical trials and in vitro studies to evaluate their efficacy, pharmacological mechanisms of action and tolerability profile. In accordance to its homeopathic nature, the medicines are also evaluated by the anthroposophic medicine concept. Biopuncture is a parenteral administration technique for these medications e follows the somatotopy and reference cutaneous areas principles. The medicine administration can be performed in subcutaneous, intramuscular, intra-articular and intravenous forms. Thousands of patients have been treated with these medications in the last sixty years with an excellent safety profile and proven efficacy for their approved indications. (AU)

Evaluating complementary therapies for canine osteoarthritis--Part II: a homeopathic combination preparation (Zeel).

A homeopathic combination preparation (HCP) for canine osteoarthritic pain was evaluated in a randomized, double-controlled and double-blinded clinical trial. Forty-four dogs with osteoarthritis (OA) that were randomly allocated into one of three groups completed the study. All dogs were fed test products or placebo for 8 weeks. The dogs were evaluated at the clinic four times, with 4-week intervals. Six different variables were assessed: veterinary-assessed mobility, two force plate variables, an owner-evaluated chronic pain index and pain and locomotion visual analogue scales (VASs). Intake of extra non-steroidal anti-inflammatory drugs was also evaluated. A Chi-squared test and a Mann-Whitney test were used to determine significant improvement between groups. When changed into dichotomous responses of 'improved' or 'not improved' three out of the six variables showed a significant difference (P = 0.016, P = 0.008, P = 0.039) in improved dogs per group, between the HCP group and the placebo group. The odds ratios were over one for the same variables. As extent of improvement in the variables from start to end of treatment, the HCP product was significantly more improved in four (P = 0.015, P = 0.028, P = 0.049, P = 0.020) of the six variables, compared with the placebo. Our results indicated that the HCP Zeel(R) was beneficial in alleviating chronic orthopedic pain in dogs although it was not as effective as carprofen.